...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low-molecular weight heparin.
【24h】

Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low-molecular weight heparin.

机译:皮下分离或低分子量肝素治疗深静脉血栓形成过程中止血系统激活的标志物。

获取原文
获取原文并翻译 | 示例
           

摘要

Prothrombin fragments (F1+2), thrombin-antithrombin complexes (TAT) and D-dimers, markers of hemostatic system activation, were measured in 59 consecutive patients with deep vein thrombosis (DVT). Patients were randomly treated either with subcutaneous unfractionated heparin (UH) administered in two to three subcutaneous doses adjusted to activated partial thromboplastin time (APTT) or with low-molecular weight heparin (LMWH) (dalteparin) administered in a fixed dose of 200 IU/kg body weight in one subcutaneous injection daily. Before treatment, F1+2, TAT and D-dimer were above the cut-off level in 27/59 (46%), 34/59 (58%) and all (100%) patients, respectively. Significant associations were observed between F1+2 and TAT (r=.66, P<.001), TAT and D-dimer (r=.36, P<.005) and F1+2 and D-dimer (r=.30, P<.050). On the third day of treatment, F1+2 and TAT significantly decreased to reference values in almost all patients (in 64/66 determinations of both F1+2 and TAT) and remained low on the seventh day of treatment. Compared to pretreatment values, a nonsignificant decrease of D-dimer was noted in both groups, but all values remained above the cut-off value. When markers of hemostatic system activation in the UH and LMWH groups were compared, no significant differences were observed. It was concluded that subcutaneous UH in an APTT-adjusted dose and subcutaneous LMWH in a once-daily weight-adjusted dose controlled these markers of hemostatic system activation in a similar manner.
机译:在连续59例深静脉血栓形成(DVT)患者中测量了凝血酶原片段(F1 + 2),凝血酶-抗凝血酶复合物(TAT)和D-二聚体,它们是止血系统激活的标志。患者随机接受皮下未分级肝素(UH)的皮下注射,调节剂量为激活的部分凝血活酶时间(APTT)2-3次,或低分子量肝素(LMWH)(达肝素)固定剂量200 IU /每天皮下注射1千克体重。治疗前,F1 + 2,TAT和D-二聚体分别高于27/59(46%),34/59(58%)和所有(100%)患者的临界水平。在F1 + 2和TAT(r = .66,P <.001),TAT和D-二聚体(r = .36,P <.005)与F1 + 2和D-二聚体(r =。 30,P <.050)。在治疗的第三天,几乎所有患者中的F1 + 2和TAT均显着降至参考值(在F1 + 2和TAT的64/66测定中),并在治疗的第七天保持较低水平。与预处理值相比,两组的D-二聚体均无明显下降,但所有值均保持在临界值以上。比较UH和LMWH组的止血系统激活标记后,未观察到显着差异。结论是,APTT调整剂量的皮下UH和每日一次体重调整剂量的皮下LMWH以相似的方式控制了这些止血系统激活的标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号